BioLine Rx (BioLine Rx) Debt-to-Revenue : 0.60 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BioLine Rx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.67 Mil. BioLine Rx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.92 Mil. BioLine Rx's annualized Revenue for the quarter that ended in Dec. 2023 was $19.20 Mil. BioLine Rx's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.60.

BioLine Rx Debt-to-Revenue Historical Data

The historical data trend for BioLine Rx's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Debt-to-Revenue Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

2.42

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	0.60

Competitive Comparison of BioLine Rx's Debt-to-Revenue

For the Biotechnology subindustry, BioLine Rx's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Debt-to-Revenue falls into.

BioLine Rx Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BioLine Rx's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.673	+	7.918)	/	4.8
	=	2.41

BioLine Rx's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.673	+	7.918)	/	19.2
	=	0.60

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

BioLine Rx Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.